NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 57 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2016. The put-call ratio across all filers is 6.52 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,695,000 | -26.9% | 2,659,497 | +5.0% | 0.00% | – |
| Q3 2016 | $2,320,000 | +307.7% | 2,533,843 | +136.1% | 0.00% | – |
| Q2 2016 | $569,000 | -74.1% | 1,073,061 | -53.9% | 0.00% | – |
| Q1 2016 | $2,200,000 | -30.0% | 2,329,054 | -1.4% | 0.00% | -100.0% |
| Q4 2015 | $3,142,000 | -36.5% | 2,362,157 | +8.8% | 0.00% | 0.0% |
| Q3 2015 | $4,948,000 | +111.3% | 2,170,115 | +49.2% | 0.00% | – |
| Q2 2015 | $2,342,000 | -5.7% | 1,454,959 | -6.8% | 0.00% | – |
| Q1 2015 | $2,483,000 | -16.7% | 1,561,636 | -0.9% | 0.00% | – |
| Q4 2014 | $2,980,000 | +22.8% | 1,576,479 | -14.2% | 0.00% | – |
| Q3 2014 | $2,426,000 | -10.1% | 1,837,936 | +0.8% | 0.00% | – |
| Q2 2014 | $2,698,000 | -9.7% | 1,822,749 | +12.8% | 0.00% | -100.0% |
| Q1 2014 | $2,989,000 | -10.9% | 1,615,871 | -0.3% | 0.00% | 0.0% |
| Q4 2013 | $3,354,000 | -27.4% | 1,620,233 | -7.1% | 0.00% | 0.0% |
| Q3 2013 | $4,623,000 | -20.3% | 1,744,388 | -19.7% | 0.00% | 0.0% |
| Q2 2013 | $5,803,000 | – | 2,173,553 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
| Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
| DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
| STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
| Hudock, Inc. | 30,500 | $63,000 | 0.05% |
| BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
| TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
| NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
| BOLTON LP | 77,400 | $160,000 | 0.03% |